Www.auritecpharma.com www.auritecpharma.com Sustained release tenofovir and maraviroc from an intravaginal ring in sheep World AIDS Conference July 2012.

Slides:

Advertisements

Similar presentations

Drug design and testing,. Drug Names Chemical name- describes its molecular structure and distinguishes it from other drugs.

Advertisements

Gilead’s Tech Transfer Partnerships and IP in India

What do we know? How do we move forward? Student Thinking Engagement Collaboration Questioning Visibility.

Test practice Multiplication. Multiplication 9x2.

Chapter Sixteen Science, Technology, and Global Health.

Telling Time; Telling the Truth Engaging communities as stakeholders (and partners) in HIV vaccine R&D Mitchell Warren AVAC 2 July 2013 IAS Symposia Session:

HIV Treatment and Intellectual Property Rights: The Experience of the Medicines Patent Pool Esteban Burrone Melbourne – International AIDS Conference July.

 Biomedical HIV Prevention strategies Wim Vandevelde European AIDS Treatment Group (EATG) European Community Advisory Board (ECAB) Conference on HIV Infection.

News You Can Use… Lauren Gray, PharmD Candidate February 2015.

Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.

Use of Antivirals in Prevention Oral and Topical Prophylaxis

The 4 th Decade of the HIV Epidemic: Midwest Regional Response September 17, 2013 with Jim Pickett, AFC/IRMA The Bottom Line on Rectal and Vaginal Microbicide.

Jim Pickett, IRMA/AFC GMHC – January 23, 2013 The Bottom Line on Rectal Microbicide Research.

Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.

1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.

Judy Manning, PhD Office of Population and Reproductive Health Bureau for Global Health From Ideal to Real: What’s in the MPT pipeline? “New Products,

Topical, Oral; Daily, Intermittent; Single, Combination agents; What do we need AND what will work? Patrick Ndase, Microbicide Trials Network & Dep’t of.

Slide 1 of 9 From J Marrazzo, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Jeanne Marrazzo, MD, MPH Professor of Medicine University of Washington.

Chapter 20: Conclusion and Future Directions The following visuals are scans of illustrations in the text. Each figure is labeled by the figure number.

XIX International AIDS Conference

1 Michael V. Novinski President and Chief Executive Officer November 6, 2008 Third Quarter 2008 Earnings Conference Call.

© IAS–USA Johnson VA et al. Top Antivir Med. 2011;19(4): Updates, user notes, and references available at Mutations in the.

Company: Name: Date:. Overview In today’s challenging business environment, your customers want low-cost, high- performance solutions. They are looking.

Moving the Rectal Microbicide Agenda Forward; Results from a Scientific, Ethical, and Community Consultative Process Ian McGowan MD PhD FRCP University.

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,

When Will Women Have Choices? Sharon Hillier University of Pittsburgh School and Medicine Microbicide Trials Network IAS, Washington DC, July 26, 2012.

AIDS 2012 Where are we, and where are we going? Mitchell Warren Executive Director, AVAC August 15, 2012.

Ethics in a new era Microbicides 2012 Preconference Bridget Haire.

International Partnership for Microbicides Vaginal Rings and Microbicides Mark Mitchnick, MD. October 30, 2007.

Novel Intravaginal Delivery of Antiretroviral-based Microbicides for HIV Prevention HIV/AIDS research Simi Gunaseelan, Ph.D. Assistant Professor of Pharmaceutical.

Cochlear Implants: A Closer Look 11/13/2006. What is a Cochlear Implant (CI)? According to the National Institute on Deafness and other Communication.

Pathology Visions Conference Giri Iyer General Manager, Strategic Development Integrated IT Solutions 10/22/2007 Digital Pathology HCIT Visions – A GE.

By TJ Wittmer Muscle weakness. Slurred speech. Also it is very difficult swallow.

Washington D.C., USA, July 2012www.aids2012.org Patent Oppositions in Argentina International AIDS Conference July 2012 M. Lorena Di Giano.

FDA Regulation Economically Harmful & Morally Indefensible.

Microbicides and PrEP: Back to Basics Wednesday July 25, 2012 ADM Kashuba.

Modified release products. Considerations in the evaluation of modified release products Requirements for preparing extended release products. The bioavailability.

Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.

FDA Draft Guidance Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved.

Peter Karlton 1 Regulatory Challenges A Diversity of Considerations Ethical Cultural Regulatory standards Strained resources Competing priorities Training.

September 20, 2010 Objective: Review Scientific method to prepare for a quiz tomorrow. Do Now: Complete sponge bob handout on scientific method. HW: Read.

ISIA Traceability Certification. Why Traceability Matters Customers and regulators continue to be concerned about the potential for adventitious agent.

© IAS–USA Johnson VA et al. Top Antivir Med. 2013;21(1):4-12. Updates, user notes, and references available at Mutations in the Reverse.

Optimizing the Paediatric ARV Pipeline Nandita Sugandhi Clinton Health Access Initiative &IATT CSWG ICASA 2015, Harare Zimbabwe November 30, 2015.

HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.

In vitro - In vivo Correlation

IPDA Web Development Project Report IPDA Steering Committee Meeting July, 2012 Emily Law, Sean Hardman, Sean Kelly, Pedro Osuna, Dan Crichton.

Welcome To Discount Pharmacy Pills Index Information About Us Generics Contact us.

RAL + MVC + DRV/r + TDF-FTC

Multiplication table. x

ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:

Does Pharmacology Support Topical PrEP?

Dissolution testing and in vitro in vivo correlation of conventional and SR preparations Formulation development and optimization is an ongoing process.

SESSION TITLE PRESENTERS

A Decade of Data Scott Billman, Biogen

סמים וסינפסות.

Bio-Facility Qualification, Start-Up & Licensure

Drug design and testing,

Setting the Stage for PrEP Where are we now, and where should we go?

تسلیم کالای جانشین توسط بایع Deliver of Substitute Goods

Доц. д-р Никола Гешковски Институт за Фармацевтска технологија

Analytical Method Validation PAI Readiness / Certification

Rectal Gels for PrEP Are They an Option?

_ _ eses ' ' l J-J - ",",.-' a c 'j..., s9aCs9aC 7.. t::J.

EFdA, a Reverse Transcriptase Inhibitor, Potently Blocks HIV-1 Ex Vivo Infection of Langerhans Cells within Epithelium Takamitsu Matsuzawa, Tatsuyoshi.

$14.47/EA $23.58/EA We currently have the thick Hydrofera blue on PAR’s, we will be moving to the “standard” version on PAR’s. These are only on specialty.

Маңғыстау облысы, Маңғыстау ауданы, Өтес селосы

Change Proposals – PARR report changes

Presentation transcript:

Sustained release tenofovir and maraviroc from an intravaginal ring in sheep World AIDS Conference July 2012 Presenter: TJ Smith

In vivo levels of TDF and MVC World AIDS Conference July 2012 Presenter: TJ Smith

Which drug(s)? Where? How much? Nobody knows. The ideal microbicide ring? Low-cost to manufacture Ability to deliver multiple drugs independently Ability to easily change drugs as new candidates become available Use of FDA approved ARTs World AIDS Conference July 2012 Presenter: TJ Smith